Researchers at Toronto’s Princess Margaret Cancer Centre have landed on a new biomarker that can predict if patients with acute myeloid leukemia will respond…

Abbott has been squirming for months over its Alere acquisition, even offering the diagnostics maker $50 million to exit the deal. Now, Abbott is putting its…

After looking into a local Medtronic unit for monopolistic activities, Chinese regulators are charging the company 118.5 million yuan ($17.2 million).

Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.

Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.

Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.

French digital health player Voluntis snagged a CE mark and FDA clearance for its management device for Type 2 diabetics who are treated with basal insulin.

TiGenix is aiming to net $42.9 million in a Nasdaq IPO, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease candidate…